Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

Core Insights - Rein Therapeutics has received authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to initiate its Phase 2 "RENEW" clinical trial for LTI-03, targeting idiopathic pulmonary fibrosis (IPF) [1][3] Company Overview - Rein Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications [5] - The lead product candidate, LTI-03, is a synthetic peptide designed to target fibrosis and protect lung tissue regeneration [5] Disease Context - Idiopathic pulmonary fibrosis (IPF) is a serious lung disease affecting hundreds of thousands globally, with a median survival of 3-5 years post-diagnosis [2] Clinical Trial Details - The RENEW trial aims to enroll up to 120 patients worldwide, comparing two dose groups of LTI-03 against a placebo [4] - The primary objective is to assess safety and tolerability over 24 weeks, with secondary endpoints including lung function and fibrosis progression assessments [4] Future Outlook - Initial data from the RENEW trial is expected in 2026, with patient recruitment actively underway in the UK [4]